NCT06439524View on ClinicalTrials.gov

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

February 15, 2026

Study Completion Date

August 15, 2026

Conditions
Endometriosis
Interventions
DRUG

40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate

if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis

Trial Locations (1)

19096

RECRUITING

Main Line Health, Wynnewood

Sponsors

Lead Sponsor

Main Line Health

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Sumitomo Pharma Switzerland GmbH

INDUSTRY

lead

Main Line Health

OTHER

NCT06439524 - The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial | Biotech Hunter | Biotech Hunter